11.15
price up icon5.89%   0.62
after-market Handel nachbörslich: 10.97 -0.18 -1.61%
loading

Indaptus Therapeutics Inc Aktie (INDP) Neueste Nachrichten

pulisher
Jun 13, 2025

Indaptus Therapeutics (INDP) Secures $2.3M Through Convertible N - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Indaptus Therapeutics raises $2.3 million through convertible notes By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Indaptus Therapeutics Announces Sale Of $2.3 Million In Private Placement Of Convertible Notes And Warrants - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

Indaptus Therapeutics Completes $2.3M Private Placement - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

Indaptus Therapeutics, Inc. Secures $2.3 Million Through Convertible Promissory Notes and Warrants in Funding Round - Nasdaq

Jun 13, 2025
pulisher
Jun 13, 2025

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants - The Manila Times

Jun 13, 2025
pulisher
Jun 13, 2025

Bitcoin Depot Adds to Bitcoin Treasury Holdings Amid Continued Market Momentum - The Manila Times

Jun 13, 2025
pulisher
Jun 13, 2025

Clinical-Stage Biotech Indaptus Raises $2.3M from Healthcare Investor to Advance Cancer Treatment Trials - Stock Titan

Jun 13, 2025
pulisher
Jun 06, 2025

Pre-market Movers: BDTX, CRGX, PASG, RGC... - RTTNews

Jun 06, 2025
pulisher
Jun 06, 2025

Breakthrough Pediatric Cancer Drug Could Unlock $155M FDA Voucher as OS Therapies Pursues RMAT Status - Stock Titan

Jun 06, 2025
pulisher
Jun 05, 2025

Summit Therapeutics Readies Major Ivonescimab Development Update for Goldman Sachs Healthcare Conference - Stock Titan

Jun 05, 2025
pulisher
Jun 03, 2025

Estrella's $3.35M Funding Accelerates Novel T-Cell Therapy Trial for Non-Hodgkin's Lymphoma - Stock Titan

Jun 03, 2025
pulisher
Jun 03, 2025

INDP stock touches 52-week low at $0.31 amid sharp annual decline By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

INDP stock touches 52-week low at $0.31 amid sharp annual decline - Investing.com India

Jun 03, 2025
pulisher
Jun 02, 2025

Indaptus Therapeutics (INDP) Advances Clinical Trial with Decoy2 - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab - The Manila Times

Jun 02, 2025
pulisher
Jun 02, 2025

Breakthrough Cancer Trial: Indaptus Tests Novel Immunotherapy Combo for Checkpoint Inhibitor Resistant Tumors - Stock Titan

Jun 02, 2025
pulisher
May 29, 2025

Indaptus Therapeutics (NASDAQ:INDP) Trading Down 1.9% – What’s Next? - Defense World

May 29, 2025
pulisher
May 29, 2025

Autoimmune Disease Biotech Dianthus Therapeutics CEO Takes Stage at Major Jefferies Conference - Stock Titan

May 29, 2025
pulisher
May 28, 2025

BNY Mellon Credit Fund's Last Distribution: $2.00 Payout Coming Before August Liquidation - Stock Titan

May 28, 2025
pulisher
May 14, 2025

Indaptus Therapeutics (INDP) Advances Clinical Trials and Expands Patent Portfolio | INDP Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

INDP Faces Funding Needs as Cash Reserves Decline | INDP Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Indaptus Therapeutics reports Q1 EPS (32c) vs. (45c) last year - TipRanks

May 14, 2025
pulisher
May 14, 2025

Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times

May 14, 2025
pulisher
May 14, 2025

Indaptus Therapeutics Q1 2025 Financial Results and Corporate Update - TradingView

May 14, 2025
pulisher
May 14, 2025

Indaptus Therapeutics, Inc. SEC 10-Q Report - TradingView

May 14, 2025
pulisher
May 14, 2025

Indaptus Launches Key Cancer Drug Combination Trial as Q1 Cash Drops to $3.9MWhat's Next? - Stock Titan

May 14, 2025
pulisher
May 13, 2025

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference - Stock Titan

May 13, 2025
pulisher
May 13, 2025

Indaptus Therapeutics (INDP) Expected to Announce Quarterly Earnings on Wednesday - Defense World

May 13, 2025
pulisher
May 11, 2025

Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025 - marketscreener.com

May 11, 2025
pulisher
May 09, 2025

Closing Figures Unveiled: Indaptus Therapeutics Inc (INDP) Gain 7.96, Closes at 0.71 - DWinneX

May 09, 2025
pulisher
May 08, 2025

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit - The Manila Times

May 08, 2025
pulisher
May 07, 2025

Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference - Stock Titan

May 07, 2025
pulisher
May 06, 2025

Loar Holdings Q1 2025 Earnings Call: How to Join the May 13 Investor Presentation - Stock Titan

May 06, 2025
pulisher
May 05, 2025

Luminar Reveals Major Business Overhaul: Strategic Restructuring and Cost Cuts Coming with Q1 Earnings - Stock Titan

May 05, 2025
pulisher
Apr 29, 2025

Mark Your Calendar: Millrose Properties Q1 2025 Earnings Coming May 14Key Details Here - Stock Titan

Apr 29, 2025
pulisher
Apr 22, 2025

Sandisk Key Q3 Financial Results: How to Access the May 7 Earnings Call - Stock Titan

Apr 22, 2025
pulisher
Apr 21, 2025

Healthcare Giant Concentra's $55M Pivot Deal Adds 200 Workplace Clinics Across 40 States - Stock Titan

Apr 21, 2025
pulisher
Apr 17, 2025

BeiGene Earnings Preview: Q1 Results Coming May 7 as Company Transforms to BeOne Medicines - Stock Titan

Apr 17, 2025
pulisher
Apr 15, 2025

Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Update - Defense World

Apr 15, 2025
pulisher
Apr 10, 2025

Claritev Earnings Preview: Q1 2025 Results Coming May 8What to Watch - Stock Titan

Apr 10, 2025
pulisher
Apr 09, 2025

Fortune 500 Retail Giant QVC Group Sets Stage for Crucial Q1 2025 Earnings Reveal - Stock Titan

Apr 09, 2025
pulisher
Mar 26, 2025

Indaptus Therapeutics Inc (NASDAQ: INDP) Stock Is Down -10.94% From Its Low: The Uptrend Is Still On - Stocks Register

Mar 26, 2025
pulisher
Mar 25, 2025

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

Top Biotech CMO Summit Taps Indaptus Expert to Guide Clinical Trial Excellence Discussion - Stock Titan

Mar 25, 2025
pulisher
Mar 24, 2025

$1 Million Winner: Berkshire Employee Nails 31 of 32 March Madness Picks - Stock Titan

Mar 24, 2025
pulisher
Mar 22, 2025

Selling Your Indaptus Therapeutics Inc (NASDAQ: INDP) Stock? Here’s What You Need To Know - Stocks Register

Mar 22, 2025
pulisher
Mar 21, 2025

Indaptus Therapeutics looks to raise $2.25M in private placement - MSN

Mar 21, 2025
pulisher
Mar 20, 2025

Indaptus reports progress in Decoy20 cancer therapy trial By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

INDP stock touches 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

INDP stock touches 52-week low at $0.7 amid market challenges - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Indaptus Therapeutics Says New Data on Decoy20 Shows Broad Immune System Activation in Cancer Patients - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

Indaptus reports progress in Decoy20 cancer therapy trial - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

Breakthrough: Indaptus Cancer Drug Successfully Activates Immune System in Weekly Dosing Trial - Stock Titan

Mar 20, 2025
pulisher
Mar 19, 2025

Indaptus tests new cancer therapy combination By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 19, 2025

CERo Therapeutics Locks Critical Manufacturing Partner for Groundbreaking Leukemia Treatment Trial - Stock Titan

Mar 19, 2025
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Kapitalisierung:     |  Volumen (24h):